An AAV dual vector strategy ameliorates the Stargardt phenotype in adult Abca4-/- mice.

The recent approval in the US of the first adeno-associated viral (AAV) vector for the treatment of an inherited retinal degeneration validates this approach for the treatment of many other diseases. A major limiting factor continues to be the size restriction of the AAV transgene at under 5kb. Stargardt disease is the most prevalent form of recessively inherited blindness and is caused by mutations in ABCA4, which has a coding sequence length of 6.8kb. Dual vector approaches increase the capacity of AAV gene therapy but at the cost of substantially reduced levels of target protein, which may be insufficient to achieve a therapeutic effect. Here we show that the efficacy of recombination of dual vectors is dependent on the length of DNA overlap between two transgenes. With optimized recombination, full length ABCA4 protein is expressed in the photoreceptor outer segments of Abca4-/- mice at levels sufficient to reduce bisretinoid formation and correct the autofluorescent phenotype. These observations support a dual vector approach in future clinical trials using AAV gene therapy to treat Stargardt disease.